All In Biotech

Free tool

FAERS Monitor: Siliq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761032 or its brand name (Siliq, Brodalumab). Reports on generic versions are filed under their own applications.

Reports

2,061

Serious

1,808

88% of reports

Hospitalization

583

Death reported

145

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • psoriasis504
  • drug ineffective240
  • arthralgia195
  • intentional product use issue180
  • psoriatic arthropathy177
  • fatigue174
  • product dose omission issue145
  • disease recurrence139
  • therapy interrupted139
  • headache131
  • off label use128
  • inappropriate schedule of product administration123
  • diarrhoea94
  • pain in extremity91
  • therapy cessation88

Reports by year received

View as table
YearReports
20131
20153
20167
20178
2018118
2019208
2020186
2021238
2022341
2023244
2024254
2025289
2026164

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,098 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
psoriatic arthropathySignal17744.738.87,499
psoriasisSignal50439.536.618,934
disease recurrenceSignal13929.925.53,851
intentional product use issueSignal18021.018.33,418
therapy interruptedSignal13919.916.92,478
therapy cessationSignal8817.514.31,356
inappropriate schedule of product administrationSignal1237.05.9628
product dose omission issueSignal1455.04.3471
arthralgiaSignal1954.84.2592
pain in extremitySignal913.22.6133
fatigueSignal1742.32.0129
headacheSignal1312.11.880
drug ineffective2401.91.7101
off label use1281.51.321
diarrhoea941.51.215

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.